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Two different workflows were tested in order to develop
methods that provide deeper insight into the secreted
O-glycoproteome. Bovine serum samples were subjected
to lectin affinity-chromatography both at the protein- and
peptide-level in order to selectively isolate glycopeptides
with the most common, mucin core-1 sugar. This enrich-
ment step was implemented with either protein-level
mixed-bed ion-exchange chromatography or with pep-
tide-level electrostatic repulsion hydrophilic interaction
chromatography. Both methods led to at least 65% of the
identified products being glycopeptides, in comparison to
25% without the additional chromatography steps
[Darula, Z., and Medzihradszky, K. F. (2009) Affinity en-
richment and characterization of mucin core-1 type gly-
copeptides from bovine serum. Mol. Cell. Proteomics 8,
2515–2526]. In order to improve not only the isolation but
also the characterization of the glycopeptides exoglyco-
sidases were used to eliminate carbohydrate extensions
from the directly peptide-bound GalNAc units. Conse-
quent tandem MS analysis of the mixtures using higher-
energy collision-dissociation and electron-transfer disso-
ciation led to the identification of 124 glycosylation sites in
51 proteins. While the electron-transfer dissociation data
provided the bulk of the information for both modified
sequence and modification site assignment, the higher-
energy collision-dissociation data frequently yielded con-
firmation of the peptide identity, and revealed the pres-
ence of some core-2 or core-3 oligosaccharides. More
than two-thirds of the sites as well as the proteins have
never been reported modified. Molecular & Cellular Pro-
teomics 11: 10.1074/mcp.O111.016774, 1–10, 2012.
Glycosylation is one of the most frequent post-translational
modifications of proteins. It is estimated that over 50% of all
proteins undergo glycosylation during their lifespan (1). Apart
from the regulatory O-GlcNAc modification, glycosylation oc-
curs mostly on secreted proteins and extracellular domains of
membrane proteins. Altered physiological conditions such as
pregnancy (2) or disease including cancer (3, 4) may result in
different glycosylation of target proteins involved. Hence, gly-
coprofiling is an indispensable part of biomarker research. Un-
fortunately, characterization of protein glycosylation of complex
samples such as serum is a rather challenging task mainly
because of two factors. First, bodily fluids usually feature a high
background of nonglycosylated proteins. Moreover, modified
sequences are frequently also present unmodified (heterogene-
ity), and when occupied, the same site may be modified with
different carbohydrate structures (microheterogeneity). Second,
up to now there is no single analytical approach that can readily
identify both the glycosylation sites and the modifying sugar
structures.
Glycosylation analysis of complex mixtures is usually re-
stricted to N-glycosylation. This is because O-glycosylation
lacks those features that facilitate N-glycosylation analysis;
namely, a consensus sequence for modification and a single
core structure for modification. Single sugar units as well as
short or complex extended structures can modify Ser, Thr,
and as recently reported Tyr residues (5, 6). For this reason
there is no universal enzyme that can cleave all the O-linked
carbohydrates (in the way e.g. PNGaseF can for N-linked
glycopeptides), and those glycosidases that eliminate certain,
well specified sugar structures leave an unmodified amino
acid and thus no trace of the previous modification site.
Sugar-elimination under basic conditions followed by Mi-
chael-addition has been used for the characterization of O-
glycosylation (7), but its efficiency varies for the different sugar
structures, definitely slower for Thr, and phosphorylated, sul-
fated, even unmodified Ser residues may also undergo the
same reactions as well as alkylated Cys residues (7–9).
In the last two decades mass spectrometry has inevitably
become the method of choice for protein characterization
including post-translational modification analysis. However,
MS characterization of O-glycopeptides by collision-induced
dissociation (CID)1 activation is ineffective at identifying the
peptide as sugar oxonium ions and fragment ions corre-
From the ‡Proteomics Research Group, Biological Research Cen-
ter of the Hungarian Academy of Sciences, Szeged, H-6701, Szeged,
POB 521, Hungary; §Department of Pharmaceutical Chemistry, Uni-
versity of California San Francisco, San Francisco, California 94158
Received December 20, 2011, and in revised form, February 3,
2012
Published, MCP Papers in Press, March 5, 2012, DOI 10.1074/
mcp.O111.016774
1 The abbreviations used are: CID, collision-induced dissociation;
AGC, automatic gain control; CV, column volume; ECD, electron
capture dissociation; ERLIC, electrostatic repulsion hydrophilic inter-
action chromatography; ETD, electron transfer dissociation; GlcNAc,
N-acetyl glucosamine; GalNAc, N-acetyl galactosamine; HCD, high-
er-energy collision-dissociation; Hex, hexose; HexNAc, N-acetyl-hex-
osamine; mixedIEX, ion exchange on a mixed-bed column; SA, sialic
acid; TEAP, triethylammonium phosphate.
Technological Innovation and Resources
© 2012 by The American Society for Biochemistry and Molecular Biology, Inc.
This paper is available on line at http://www.mcponline.org
Molecular & Cellular Proteomics 11.7 10.1074/mcp.O111.016774–1
sponding to carbohydrate fragmentation dominate MS/MS
spectra. On the other hand, electron capture dissociation (10)
and electron transfer dissociation (ETD) (11) analysis of gly-
copeptides is a more successful approach in this respect
[ECD: 5,12; ETD: 6,13,14], despite the fact that these activa-
tion techniques are less efficient compared with CID, work
considerably better on higher charge state peptide precursors
and have significant precursor m/z limitations (15).
Currently, for successful ETD-based O-linked glycopeptide
characterization one has to know either the protein(s) or the
sugar structure to begin with. General glycopeptide enrich-
ments as hydrophilic interaction liquid chromatography (16) or
selective capture/release based on the unique properties of
sialic acid (17) presently cannot be combined with large scale
automated studies. Although CID data can provide informa-
tion about sugar structure and ETD can characterize peptide
sequence, there is currently no automated way to correlate
these two types of data. Hence, only a fraction of glycopep-
tides enriched in a nonstructure-specific fashion can be char-
acterized and it is done manually (17). Thus, either one can
characterize glycosylation within a protein mixture of limited
complexity (proteins identified from a strict database search
can be subjected to a second search where undefined mod-
ifications over a mass range are considered (18)) or one has to
apply some oligosaccharide-selective enrichment strategy for
the glycopeptides, so that the database search could be
restricted to a few sugar compositions.
Jacalin, a lectin isolated from Artocarpus integrifolia has
been reported binding GalNAc1-modified glycopeptides in
which C6-OH is free, but not recognizing such structures with
substitution at the C6 position (19). Previously we have shown
that Jacalin affinity-chromatography combined with MS-anal-
ysis by CID and ETD fragmentation is a viable experimental
setup for characterization of the core-1 mucin-type glycopro-
teome of serum (14). However, our findings were restricted to
the more abundant proteins of serum. In order to gain a
deeper insight, we have now combined the affinity-enrich-
ment with other protein- or peptide-level fractionations, and
tested two different workflows.
In the protein-level fractionation approach, ion-exchange
chromatography was implemented for fractionation of the
glycoprotein mixture isolated by Jacalin lectin affinity-chro-
matography. Because of its high sample capacity, ion ex-
change is a popular method for separation of protein samples.
Using a mixed-bed ion-exchange column that contains anion-
exchange and cation-exchange material in equal amounts
enables the retention and fractionation of proteins over the
entire pI range (20). A further advantage of this separation
step is that even abundant proteins are expected to be re-
stricted to a few fractions, thus increasing the chances for the
identification of less abundant glycoproteins.
In the peptide-level approach, the tryptic digest of the gly-
coprotein mixture isolated by Jacalin lectin affinity-chroma-
tography was subjected to further separation applying the
ERLIC (electrostatic repulsion hydrophilic interaction chroma-
tography) principle (21). ERLIC is a mixed mode chromatog-
raphy where the retention of any given compound depends on
the combination of electrostatic repulsion from and hydro-
phylic interaction with the solid support (21). In the case of
tryptic digests, unmodified peptides are expected to be pro-
tonated at pH 2 and therefore elute in the flow-through or
early eluting fractions, whereas peptides modified by highly
acidic groups such as phospho- and sulfopeptides, and sia-
lylated glycopeptides are retained longer. As a result, sialy-
lated glycopeptides can be selectively isolated from unmod-
ified peptides. Although this workflow was expected to be
limited to the selective isolation of sialylated glycopeptides, in
our pilot studies the majority of the glycopeptides bore sialic
acid residues. Therefore we did not consider this as a major
limitation.
In this study glycopeptide enrichment results are compared
from the two above described workflows. In order to ensure
higher identification rates, i.e. to overcome the charge-density
limits for successful ETD experiments, glycopeptides were
treated with neuraminidase and -galactosidase, and the se-
quences retaining only the core GalNAc units were subjected
to MS/MS analysis using both HCD and ETD activation. We
identified 124 glycosylation sites in 51 glycoproteins; an 6-
fold improvement in comparison to our previous results, when
only lectin affinity-chromatography was used. Thirty-five of
the proteins were previously not known to be glycosylated.
Similarly, more than half of the sites determined represent
novel glycosylation sites.
EXPERIMENTAL PROCEDURES
Chromatography was performed on a Jasco semimicro HPLC sys-
tem complete with a four-line degasser (DG-2080–54, Jasco), two
pumps (PU2085, Jasco), a dynamic mixer (MX 2080–32, Jasco), a
UV-VIS detector (Spectra-Flow 501, Sunchrom), and a fraction col-
lector (CHF 122 SC, Advantec).
Glycoprotein Isolation by Jacalin Affinity Chromatography—Chro-
matography was performed as previously published (14), 2 ml of fetal
calf serum was injected onto a 1 mm 2000 mm (CV:1.57 ml) column
packed with agarose-bound Jacalin (VectorLabs AL1153). After intro-
ducing the sample (flow rate: 50 l/min), the column was washed with
eight CV of solvent A (175 mM Tris.HCl, pH 7.5; flow rate:150 l/min)
then the species bound were eluted with five CV of solvent B (0.8 M
galactose/175 mM Tris.HCl, pH 7.5; flow rate:150 l/min) collecting
8-min fractions.
ERLIC Chromatography—The tryptic digest of the protein mixture
isolated by Jacalin affinity-chromatography was fractionated on a
weak anion-exchange column (PolyWAX LP, PolyLC Inc, 4.6 mm ID
20 cm, 5 m particle size, 300A pore size) applying the following
gradient program (flow rate: 1 ml/min, UV-detection at 215 nm): 0–5
min: 0% B, 5–15 min: 0–10% B, 15–35 min: 10–60% B, 35–45 min:
60–100% B, 45–55 min:100% B (solvent A: 20 mM methyl-phospho-
nic acid pH:2/70% acetonitrile, solvent B: 200 mM TEAP (triethyl-
ammonium phosphate) pH 2/60% ACN; the pH of solvent A and
solvent B were adjusted using 10 M aqueous NaOH and triethyl-
amine, respectively). 1-min fractions were collected, dried down to
200 l and desalted on 100 l C-18 tips (Omix, Varian) and
concentrated.
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Mixed-bed Ion Exchange Chromatography—Protein mixture iso-
lated by Jacalin affinity-chromatography from 2 ml fetal calf serum was
fractionated on a mixed-bed ion exchanger column (PolyCATWAX,
PolyLC Inc, 4.6 mm ID  20 cm, 5 m particle size, 1000 Å pore size)
applying the following gradient program (flow rate: 0.5 ml/min, UV-
detection at 275 nm): 0–5 min: 0% B, 5–15 min: 0–10% B, 15–35 min:
10–60% B, 35–45 min: 60–100% B, 45–55 min:100% B (solvent A: 20
mM ammonium acetate pH:7, solvent B: 800 mM ammonium acetate
pH:7). 2-min fractions were collected and dried down before further
treatment.
Tryptic Digestion—Samples were supplemented with guanidine
hydrochloride to give a final concentration of 6 M. Disulfide bridges
were reduced using dithiothreitol (56 °C for 30 min) and the resultant
free sulfhydryl groups were derivatized using iodoacetamide (1.1x
equivalent to dithiothreitol, 30 min in the dark at room temperature).
Samples were then diluted eightfold with 100 mM ammonium bicar-
bonate to reduce the guanidine hydrochloride concentration, and
incubated with porcine trypsin (Fluka 93614; 1% (w/w) of the esti-
mated protein content) at 37 °C for 4 h. Digestion was stopped by
adding trifluoroacetic acid (final pH 3). The resulting peptide mix-
tures were desalted on C18 reversed phase and concentrated.
Glycopeptide Isolation by Jacalin Affinity Chromatography—Chro-
matography was performed as previously described (14). The tryptic
digest of a glycoprotein mixture was injected onto a 1 mm  200 mm
(CV:0.157 ml) column packed with agarose-bound Jacalin. After in-
troducing the sample (flow rate: 50 l/min), the column was washed
with 20 CV of solvent A (175 mM Tris HCl, pH 7.5; flow rate:150 l/min)
then the species bound were eluted with 20 CV of solvent B (0.8 M
galactose/175 mM Tris.HCl, pH:7.5; flow rate:150 l/min) collecting
4-min fractions. Fractions of interest were acidified and desalted on
100 l C-18 tips (Omix, Varian) prior to further treatment. The fractions
to be purified were pulled up onto pipette-tips pretreated following
the manufacturer’s instructions, the galactose and salt were removed
with 0.1% formic acid in water (5  200 l). Peptides and glycopep-
tides were eluted with 200 l 0.1% formic acid/50% acetonitrile/
water. Samples were concentrated in a vacuum centrifuge.
Partial Deglycosylation of O-Glycopeptides (14)—Sialic acid and
-galactose units of glycopeptides were removed by incubation with
neuraminidase (5–10 U/sample, New England Biolabs P0720; in 100
mM sodium citrate, pH 6.0) for 1 h at 37 °C followed by overnight
treatment with -galactosidase (10 U/sample, New England Biolabs
P0726; in 100 mM sodium citrate, pH 4.5) at 37 °C. Enzymatic degly-
cosylation was stopped by acidification to pH 3 with 10% trifluoro-
acetic acid solution, and the resulting peptide mixtures were desalted
on 10 l C-18 tips (Millipore ZTC18S960).
Mass Spectrometry—Glycopeptide mixtures were separated on
nanoflow reversed phase HPLC (nanoAcquity, Waters, Milford, MA)
directing the eluent to nanospray sources of a linear ion trap-Orbitrap
(Velos-Orbitrap, Thermo Fisher Scientific) mass spectrometer oper-
ating in positive ion mode.
Samples were injected onto a UPLC trapping column (Symmetry,
C18 5 m, 180 m  20 mm; Waters) (15 l/min with 3% solvent B)
followed by a linear gradient of solvent B (5 to 35% in 35 min,
followed by a short wash at 50% solvent B, before returning to
starting conditions; flow rate: 400 nl/min; nanoACQUITY UPLC BEH
C18 Column, 1.7 m, 75 m  200 mm; solvent A: 0.1% formic
acid in water, solvent B: 0.1% formic acid in acetonitrile).
MS data acquisition was carried out in data-dependent fashion
acquiring sequential HCD and ETD spectra of the three most intense,
multiply charged precursor ions identified from each MS survey scan.
ETD experiments were performed in the linear trap, whereas HCD
activation was carried out in the collision cell. MS and HCD spectra
were acquired in the Orbitrap, and ETD spectra in the linear ion trap.
Ion populations within the trapping instruments were controlled by
integrated automatic gain control. For HCD, the AGC target was set
to 50,000, with dissociation at 35% of normalized collision energy,
activation time: 0.1 ms. For ETD, the automatic gain control target
values were set to 10,000 and 200,000 for the isolated precursor
cations and fluoranthene anions, respectively, and allowing 100 ms of
ion/ion reaction time. Supplemental activation for the ETD experi-
ments was enabled (supplemental activation energy: 15). Dynamic
exclusion was also enabled (mass width low: 0.5 Th, mass width high
1.5 Th), exclusion time: 45 s.
Some glycopeptides fractions were combined and analyzed on an
LTQ-Orbitrap Elite (courtesy of Thermo Scientific, San Jose, CA). A
single spectrum from this analysis that enabled unambiguous site
assignment for E1BB91 was included in the supplementary Figs.
Data Interpretation—Peaklists from LTQ-Orbitrap raw data files
were created by using the UCSF in-house peak-picking program
PAVA (22). The software generates separate HCD and ETD peaklists.
From the above ETD peaklists “glycopeptide-only” versions were
also prepared after HCD-based filtering. An in-house script (supple-
mental File S1) was used to screen HCD data for the HexNAc specific
carbohydrate ion m/z  204.087 with a mass accuracy of 0.01 Da.
Whenever such a fragment was not found, the ETD spectrum of the
corresponding precursor ion was deleted from the ETD peaklist.
Similar ETD peaklists screened for 204.087 and 366.14; and 204.087
and 407.167 (mass accuracy: 0.01 Da) were also prepared.
Database searching was performed by ProteinProspector v.5.8.1
against the UniProt database (07.06.2011), supplemented with a ran-
dom sequence for each entry, and species specified as Bos taurus
(66914/33089872 entries searched). Search parameters were as fol-
lows: trypsin was selected as the enzyme, two missed cleavages
were permitted, and nonspecific cleavages were also permitted at
one of the peptide termini. Mass accuracies of 15 ppm for precursor
ions, 20 ppm for HCD fragment ions, and 0.8 Da for ETD fragment
ions were considered. Fixed modification was carbamidomethylation
of Cys residues. Variable modifications were the acetylation of protein
N termini; Met oxidation; and the cyclization of N-terminal Gln resi-
dues; plus HexNAc modification on Thr and Ser residues. A maximum
of three modifications per peptide were permitted. Search parameters
for HCD data also included HexNAc as a variable modification subject
to neutral loss; i.e. fragments were assumed to be unmodified. Ac-
ceptance criteria were as follows: minimum peptide score: 22, mini-
mum protein score: 22; maximum peptide E-value: 0.1, maximum
protein E-value: 0.1; minimum best discriminant score: 1. SLIP score
as a measure of reliability of site assignments was set to six (23). Only
the best identification is reported for each unique sequence (consid-
ering differently modified sequences as unique).
Data was also searched permitting nonspecific cleavages at both
termini, which identified a few new glycopeptides that after careful
inspection were included in the data set (supplemental Figs.). An
additional database search was performed on the subset of identified
proteins allowing up to 4 variable modifications per peptide applying
the same acceptance criteria as above with manual validation of data
providing additional glycosylation information to the original database
search results.
With the 204 and 366 and 204 and 407-filtered peaklists separate
searches were performed. Search parameters were as above, except
HexHexNAc and HexHexNAcSA or HexNAc2 on Ser/Thr residues
were also permitted as variable modifications. Acceptance criteria
reporting those modifications were the same.
Novelty of the glycosylation site assignments is based on informa-
tion available in the UniProt database in November 2011.
RESULTS AND DISCUSSION
Previously we have shown that affinity chromatography
with agarose-bound Jacalin is a useful but limited approach
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for the isolation of mucin core-1 type O-glycosylated struc-
tures. Although we were able to determine 34 O-glycosylation
sites in 16 different proteins, evidently there are a much higher
number of O-glycoproteins in serum. In order to lower non-
specific background and enable detection of less abundant
glycoproteins and/or glycoforms, after the first protein-level
affinity enrichment, an additional fractionation step was in-
cluded into our enrichment protocol either at the protein- or
the peptide-level (Fig. 1). Although the analysis of intact gly-
copeptides would be desirable, our previous experience
showed that ETD frequently does not yield sufficient informa-
tion because of the low charge-density of these molecules
(15). We showed that this situation could be somewhat im-
proved by partial deglycosylation, i.e. retaining only the core
GalNAc units (14). Thus, this was the final step in both of our
sample preparation protocols.
In the protein-level approach mixed-bed ion-exchange
chromatography was used. It was expected that this fraction-
ation would make the less abundant glycoproteins more “vis-
ible” once they were separated from the major components.
Each fraction collected was digested with trypsin and sub-
jected to peptide-level affinity-chromatography, and then to
partial deglycosylation as described in the Experimental sec-
tion. MS characterization of these samples revealed that our
enrichment strategy was successful in significantly eliminating
nonglycosylated background—65% (400 out of 614 peptides
identified, supplemental Table S1) of the peptides identified
represented glycosylated sequences compared with 25%
achieved with affinity chromatography alone (14). As ex-
pected, new glycoproteins and glycosylation sites were iden-
tified (Table I, carefully inspected spectra corresponding to
novel glycosylation sites are presented in the supplementary
Figs.). At the same time the data also reflected poor separa-
tion efficiency of the mixed-bed ion-exchange chromatogra-
phy: as deduced from the distribution of unique sequences
representing nine abundant proteins (Fig. 2), the glycoproteins
apparently spread out covering the whole chromatographic
run. The most likely explanation for this phenomenon is that
these proteins exist in multiple glycoforms that are retained
differently. As a result the overwhelming majority of the gly-
copeptides still represented a few abundant glycoproteins.
Heterogeneity in site occupancy as well as rampant proteo-
lytic activity in serum resulting in nontryptic cleavages caused
the number of glycopeptides representing the same proteins
to multiply (supplemental Tables S1–S4).
In the other workflow tested, after the protein level affinity-
chromatography, the Jacalin-bound fraction was digested
with trypsin, then ERLIC chromatography was used for the
fractionation of the resulting peptide mixture. In our pilot
studies it was found that ERLIC fractionation in itself was
insufficient for the selective isolation of sialylated glycopep-
tides (unpublished results). In order to overcome this problem,
an affinity-enrichment was applied with Jacalin on the col-
lected ERLIC fractions. This step again was followed by partial
deglycosylation. Affinity purification combined with ERLIC also
proved to be very effective for glycopeptide isolation, 76% (473
out of 619 total peptide hits, supplemental Table S2) of the
identified sequences belonged to glycopeptides.
Identification of glycopeptides first was carried out by da-
tabase searching of HCD and ETD MS/MS data (acquired on
the isolated chromatographic fractions), independently. The
majority of the glycopeptides was identified from ETD data
(supplemental Tables S1 and S2). Although ETD spectra
provided unambiguous site assignments (See supplemental
Figs.), the presence of isomeric structures, i.e. the same se-
quences modified at different positions cannot be excluded.
The supplementary Tables clearly indicate the complexity of
the mixture and the frequent ambiguity of the site assign-
ments. HCD-based search results frequently provided confir-
mation for the identity of the modified sequences, even if the
site could not be localized from the spectra (Shown in sup-
plemental Tables S3 and S4). Although HCD data frequently
do not yield sufficient information for glycopeptide identifica-
tion, they almost always display characteristic carbohydrate
fragmentation. In order to exploit this feature for our advan-
tage, HCD data were used to screen for the presence of
glycopeptides.
An in-house script was created that searches for reporter
ions in the HCD spectra that indicate the presence of certain
carbohydrate structures (this same script can be used for
searching for other diagnostic ions, such as m/z  216 for
phosphotyrosine). Individual ions, or ion combinations, and
their relative or absolute mass accuracy can be specified, as
well as a relative intensity threshold (within the “n” most
intense fragment ions in the spectrum) (supplemental File S1).
The HCD peaklists generated from LC/MS/MS experiments
were filtered with this program. Whenever the specified ions
were absent in an HCD spectrum, the corresponding precur-
sor ion and its fragments were removed from the appropriate
FIG. 1. Enrichment strategy for mucin-type core-1
O-glycopeptides.
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TABLE I
O-glycosylation sites identified in the present study (See supplemental Figs.). Site assignments are given for the Uniprot entry corresponding
to the best characterized bovine sequence. Uniprot IDs in parantheses refer to the protein identified by database search. Names with asterisk
refer to proteins described as “uncharacterized protein”, the name of the closest well characterized (human) homolog is given. Legend for
modification sites: new; discovered by us earlier (14, 30); known confirmed now; known found earlier; known in human found now, known
in human found earlier. Reference data for known sites is given in supplemental File S2
Uniprot ID Protein name Modification site Enrichment protocol
A2I7N2 SERPINA3–6 31-gT Both
A4IFA5 VASN protein 455-gS, 460-gT Both
A5D7R6 ITIH2 protein 673-gS, 691-gT Both
A5PK77 SERPINA11 protein 387-gT mIEX
A5PKA3 CCDC80 protein 89-gT ERLIC
A6QLD8 ADAMTSL4 protein 605-gT Both
E1BB91 Collagen alpha-3(VI) chain* 2929-gT ERLIC
E1BCW0 Hepatocyte growth factor activator* 355-gT, 360-gT, 365-gT Both
E1BI67 Interleukin-18-binding protein* 50-gS ERLIC
E1BKQ9 Polypeptide N-
acetylgalactosaminyltransferase 5*
429-gT Both
F1MER7 Basement membrane-specific heparan
sulfate proteoglycan core protein*
3374-gT ERLIC
F1MMK9 Protein AMBP* 198-gT Both
F1N1I6 Gelsolin* 27-gT, 34-gT, 44-gT Both
O18977
(F1MPK6)
Tenascin-X 3146-gT or 3147-gT (682-gT
or 683-gT)
ERLIC
P00735 Prothrombin 193-gT, 205-gT, 206-gS ERLIC
P00743 Coagulation factor X 485-gT ERLIC
P00744 Vitamin K-dependent protein Z 388-gT Both
P01030 Complement C4 (fragments) 420-gT Both
P01044
(F1MNV4)
Kininogen-1 136-gT, 149-gS or 150-gT,
399-gT, 400-gT, 406-gS,
581-gS, 586-gT, 605-gT
Both
P02672 Fibrinogen alpha chain 464-gT, 525-gT ERLIC
P02676 Fibrinogen beta chain 4-gT Both
P06868 Plasminogen 366-gT, 378-gT Both
P07224 Vitamin K-dependent protein S 104-gT ERLIC
P07456
(B8QGI3)
Insulin-like growth factor 2 99-gT, 106-gT, 154-gS,
163-gT, 168-gT, 173-gS;
174-gS
Both
P07589 Fibronectin 280-gT, 2156-gT, ( 2157-gT) Both
P12763 Alpha-2-HS-glycoprotein 217-gT, 271-gS, 280-gT,
282-gS, 296-gS, 314-gT,
320-gS, 324-gS, 325-gS,
334-gT, 341-gS
Both
P17690 Beta-2-glycoprotein 1 32-gS, 33-gT mIEX
P19035 Apolipoprotein C-III 90-gS or 92-gT ERLIC
P28800 Alpha-2-antiplasmin 24-gS/27-gS/28-gT, 398-gT,
400-gT, 489-gS
24/27/28 mIEX; 398&400 ERLIC
489 both
P50448 Factor XIIa inhibitor 74-gT mIEX
P81187 Complement factor B 26-gT ERLIC
P81644 Apolipoprotein A-II 40-gT Both
Q03247 Apolipoprotein E 31-gT, 32-gT, 211-gT,
307-gS, 309-gT, 310-gS
Both
Q05717 Insulin-like growth factor-binding protein 5 171-gT ERLIC
Q0VCM5 Inter-alpha-trypsin inhibitor heavy chain H1 643-gS, 648-gT Both
Q28083 Collagen alpha-1(XI) chain (Fragment) 86-gT ERLIC
Q28107 Coagulation factor V 1151-gS, 1154-gT, 1171-gT Both
Q29RQ1 Complement component C7 696-gT mIEX
Q2KIU3 Protein HP-25 homolog 2 72-gT Both
Q32KM8 Augurin 47-gT ERLIC
Q32PI4
(F1N4M7)
Complement factor I 57-gT mIEX
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ETD data set. In our case, the HexNAc oxonium ion at m/z 
204.087, within 0.01 Da was specified as an essential glyco-
peptide-identifying fragment, and no limit was specified for
the fragment ions screened. Database searches were re-
peated with the filtered peaklists and results obtained with
these ETD-peaklists are reported in supplemental Tables S3
and S4. In addition to more confident data interpretation, the
screening also accelerates database searching. This simple
TABLE I—continued
Uniprot ID Protein name Modification site Enrichment protocol
Q3MHN2 Complement component C9 24-gT, 26-gS ERLIC(mIEX)
Q3SWW8 Thrombospondin-4 270-gT, 282-gS, 284-gT ERLIC
Q3SYR5 Apolipoprotein C-IV 35-gT ERLIC
Q3T052
Q5EA67
Inter-alpha-trypsin inhibitor heavy
chain H4
629-gS, 635-gS, 677-gS,
683-gS, 686-gS, 688-gT,
689-gS, 695-gS, 698-gT,
705-gT, 706-gT, 708-gT,
(719-gS)
Both
Q3ZBS7 Vitronectin 63-gT, 97-gT, 98-gT, 107-gT,
142-gT or 143-gS
Both
Q58CQ9 Pantetheinase 504-gT Both
Q58D34 Peptidase inhibitor 16 408-gT ERLIC
Q58D62 Fetuin-B 19-gT, 20-gS, 157-gS,
173-gT, 262-gS, 273-gT,
292-gT, 295-gT, 299-gT
Both
Q95121 Pigment epithelium-derived
factor
34-gT Both
Q9N2I2 Plasma serine protease inhibitor 35-gT, 36-gT Both
FIG. 2. Distribution of glycopeptides from nine abundant proteins in the mixed-bed ion exchange separation fractions. Different site
assignments count as unique. The x-axis in represents the elution time: 2 min fractions were collected. (The color version of this Fig. can be
seen in supplemental Table S3.) In order to illustrate the complexity of the system more liberal acceptance criteria were applied for the data
used in this Figure: discriminative score  0; peptide score 15; E  0.1; mass error  10 ppm.
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filtering procedure removed 90% of data corresponding to
nonglycosylated peptides with less than 1% or 3% of glyco-
peptide data loss in the mixedIEX and ERLIC data sets dis-
cussed here, respectively.
In order to check the efficiency of exoglycosidase treatment
and also to search for carbohydrate structures other than
mucin core-1, HCD data were also screened for the presence
of carbohydrate oxonium ion combinations, such as m/z
204.087 and 366.140, and m/z 204.087 and 407.167 (during
this screening the ions of interest had to be among the 60
most abundant HCD fragment). Combined filtering for m/z
204 and 366 identifies GalNAcGal structures present because
of incomplete deglycosylation by beta-galactosidase. The re-
sults confirmed that the enzymatic sugar removal was rea-
sonably efficient: 7.5% of the glycopeptide IDs belong to
HexNAcHex or HexNAcHexSA containing structures (supple-
mental Table S5). In addition, the filtering protocol enabled us
to identify glycopeptides with carbohydrate structures featuring
a different core: m/z  407.167 indicating a HexNAc2 structure
was detected in several HCD spectra representing four different
proteins, ITI H4 (Q5EA67), insulin-like growth factor II (P07456),
kininogen-1 isoform (F1MNV4), and hepatocyte growth factor
activator (E1BCW0) (supplemental Table S6).
Although the corresponding carbohydrate oxonium ion in-
dicates the presence of a HexNAc2 structure on these pep-
tides, the exact sites of modification usually cannot be deter-
mined from the corresponding ETD spectra due to incomplete
fragmentation. Moreover, if the right number of HexNAc mod-
ifications were permitted most of them would be assigned as
modified with single sugar units at different positions (see
supplemental Table S6). There were some exceptions, when
the site assignment was unambiguous as shown in Fig. 3. The
corresponding sugar structure evidently cannot be derived
from the core-1 Gal1–3GalNAc structure. The presence of
directly linked HexNAc units suggests core-2 and core-3
structures if one does not consider rare core structures. Al-
though only core-3 structures bind to Jacalin we cannot ex-
clude the presence of core-2 oligosaccharides. All peptides
carrying the 407.2 Da modifications were multiply glycosy-
lated and hence it is reasonable that Jacalin, specific for the
core-1 structure captured them. These differently glycosy-
lated peptides beautifully illustrate the need for carbohydrate
structural information prior to the database search with ETD
data. Without the HCD fragmentation information a significant
portion of these glycopeptides would be incorrectly assigned
or not assigned at all.
FIG. 3. HCD (upper panel) and ETD (lower panel) spectra of the E1BCW0 glycopeptide, IQPPPT(HexNAc2)EALLTLPGPT(HexNAc)
AAGPAGR. The precursor ion was at m/z 945.4967 (3). In the HCD spectrum the Gs indicate the number of sugar units on the peptide
fragment. In the ETD spectrum the fragments are fully glycosylated. However, sugar loss from the precursor ion was detected as indicated.
❖ labels the original and the charge-reduced precursor ions.
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Jacalin has been reported to display binding specificity
toward mannose residues (24). N-linked structures featuring
multiple mannose residues should yield an oxonium ion atm/z
163.0606 (25). Thus, the HCD data were screened looking for
this diagnostic fragment. However, we did not find any proof
for the presence of N-linked glycopeptides.
Summarizing the database search results for the two enrich-
ment approaches (detailed in supplemental Tables S3 and S4),
in the present study we have identified 124O-glycosylation sites
in 51 different proteins (Table I, supplementary Figs.). According
to the current Uniprot database, 76 of these sites are novel (six
of these sites were reported glycosylated in the corresponding
human homolog) and 35 of the 51 glycoproteins have not been
reported O-glycosylated previously. These results represent an
sixfold improvement compared with sample preparation by
Jacalin enrichment alone, where 21 sites were identified (14). All
the previously identified 21 sites were found with the present
protocols. Of the 51 glycoproteins identified, 28 were found with
both enrichment methods, whereas 18 and five additional gly-
coproteins were identified by the peptide-level ERLIC and the
protein-level mixed-bed ion-exchange fractionation, respec-
tively (Fig. 4A). In terms of glycosylation sites, 92 were identified
in both experiments and an additional 26 and seven glycosyla-
tion sites were identified by the ERLIC and mIEX methodology,
respectively (Fig. 4B). 73% of the total identified O-glycosylation
sites were found by both approaches, providing a level of vali-
dation to the results. The ERLIC-based enrichment performed
slightly better both in terms of the number of identified glyco-
proteins and sites of modification.
We carefully inspected the glycosylation sites identified as to
whether these would reveal any tendencies about their localiza-
tion. There are several GalNAc-transferases responsible for ini-
tiation ofO-glycosylation with distinct but overlapping substrate
specificity (26). Consequently, it is unlikely that a universal con-
sensus sequence exists for this modification. However, fre-
quency of different amino acids flanking the modification site
might be of use for further studies including prediction algo-
rithms. Residues for the six positions both “upstream and
downstream” were considered, and only unambiguous site-
assignments were included (supplemental Table S7). Interest-
ingly, more than two-thirds of the modified sequences contain
glycosylated Thr residues versus Ser modifications: 85 and 34,
respectively. The distribution of the flanking amino acids (Fig. 5)
confirms that secreted O-glycosylation primarily occurs in se-
FIG. 4. Distribution of O-glycoproteins (A) and O-glycosylation
sites (B) identified by the Jacalin-mixed-bed ion-exchange and
the Jacalin-ERLIC experiment.
FIG. 5. Amino acid distribution around the O-glycosylation sites determined (supplemental Table S7, color version also is presented
there). Ser- and Thr-specific distributions are presented in supplemental Table S8. This Figure was generated by http://weblogo.berkeley.edu/.
“The height of symbols within the stack indicates the relative frequency of each amino at that position.”
TABLE II
Glycopeptides representing the same region, Ser154-Lys175 with variable glycosylation, identified from insulin-like growth factor II
m/z z ppm DB peptide Protein mods Expect
764.1268 4 2 SHRPLIALPTQDPATHGGASSK HexNAc@1545; HexNAc2@1635; HexNAc@1745
manual evaluation
0.0029
570.8846 5 6 SHRPLIALPTQDPATHGGASSK HexNAc@15448; HexNAc@16336; HexNAc@16819 0.033
713.3555 4 4 SHRPLIALPTQDPATHGGASSK HexNAc@15457; HexNAc@16315; HexNAc@173 174 4.9e-8
840.4152 3 3 SHRPLIALPTQDPATHGGASS HexNAc@15460; HexNAc@16327 1.8e-6
611.8168 4 3 SHRPLIALPTQDPATHGGASSK HexNAc@16327 1.9e-5
788.3960 3 0 SHRPLIALPTQDPATH HexNAc2@15442; HexNAc@16318 0.019
724.0330 3 1 LIALPTQDPATHGGASSK HexNAc@16326; HexNAc@17411 8.4e-9
686.3384 3 1 IALPTQDPATHGGASSK HexNAc@16350; HexNAc@16826 0.0015
754.0312 3 2 IALPTQDPATHGGASSK HexNAc@16329; HexNAc@17324; HexNAc@17428 1.2e-6
686.3372 3 3 IALPTQDPATHGGASSK HexNAc@16322; HexNAc@1736 2.7e-8
825.9274 2 2 IALPTQDPATHGGASSK 6.4e-5
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quence stretches that are rich in Pro, Ala, Gly residues (27, 28).
Additional potential modification sites, i.e. Ser and Thr residues
also relative frequently occur in close vicinity (26). If we display
distributions unique to Ser and Thr residues some differences
start to emerge (supplemental Table S8). However, there are no
sufficient data points to draw conclusions from these
differences.
Regarding site localization within the protein sequences, the
majority of the sites are located near protein termini (59% of the
novel glycosylation sites) or near domain boundaries (an addi-
tional 13%). We have already reported this phenomenon in our
pilot studies when affinity enrichment alone was used (14). We
still do not know whether this is a bias of the affinity enrichment
protocol (i.e. the first protein-level enrichment) or indicates that
O-glycosylation is preferential to protein termini. However, O-
glycosylation has been implicated in protein processing (29),
and such a role would explain the glycosylations detected close
to processing sites. In the present study we also have identified
glycopeptides that show great variation in site occupancy (there
is also some indication of different oligosaccharide structures,
supplemental Tables S3–S6), yielding a wide variety of coexist-
ing multiply modified sequences. As an example, insulin-like
growth factor II (P07456) was found to be multiply glycosylated
on its C-terminal region (Table II) with Ser-154, Thr-163, Thr-
168, Ser-173, and Ser-174 being glycosylated either alone or in
different combinations. HCD data of glycopeptides representing
this sequence stretch revealed the presence of HexNAc2, i.e.
not only mucin core-1, but perhaps core-2 or core-3 glycan.
Such observations may suggest that for some proteins the
modification of a given region not an individual residue has
biological significance.
In conclusion, we have developed two selective sample
preparation methods that combined with partial deglyco-
sylation and HCD/ETDMS/MS analyses provide a better insight
into the secreted O-glycoproteome, albeit only such GalNAc1-
containing structures are enriched that are not modified in po-
sition C6. In addition, structural information is lost due to partial
deglycosylation. The single GalNAc identified could derive from
a T-antigen (Core 1), from its sialylated version or may represent
the original Tn-antigen present. Similarly, the HexNAc2 struc-
tures detected could derive from Core-3 structures that bind to
Jacalin, or Core-2 structures that do not bind to the lectin, but
happened to be on glycopeptides modified also with other
sugar structures of Jacalin-specific affinity.
These methods can be readily applied to urine or CSF sam-
ples providing useful tools for glycosylation analysis. However,
for the characterization of O-glycosylation in membrane pro-
teins because of the limitations in protein level fractionation, a
combination of ERLIC and lectin affinity-chromatography is
more promising.
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